Home
/
SUPERNUS PHARMACEUTICALS, INC.
/
Financials
/
Quarterly
SUPERNUS PHARMACEUTICALS, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that SUPERNUS PHARMACEUTICALS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2020
Mar 31, 2020
$94.98M
May 15, 2020
Q3
2019
Sep 30, 2019
$102.14M
Nov 8, 2019
Q2
2019
Jun 30, 2019
$104.70M
Aug 9, 2019
Q1
2020
Mar 31, 2019
$85.47M
May 15, 2020
Q3
2019
Sep 30, 2018
$103.00M
Nov 8, 2019
Q2
2019
Jun 30, 2018
$99.54M
Aug 9, 2019
Q1
2019
Mar 31, 2018
$90.43M
May 10, 2019
Q3
2018
Sep 30, 2017
$80.40M
Nov 9, 2018
Q2
2018
Jun 30, 2017
$75.83M
Aug 9, 2018
Q1
2018
Mar 31, 2017
$57.58M
May 10, 2018
Q3
2017
Sep 30, 2016
$56.81M
Nov 9, 2017
Q2
2017
Jun 30, 2016
$51.63M
Aug 3, 2017
Q1
2017
Mar 31, 2016
$44.19M
May 9, 2017
Q3
2016
Sep 30, 2015
$39.36M
Jan 20, 2017
Q2
2016
Jun 30, 2015
$35.68M
Jan 23, 2017
Q1
2016
Mar 31, 2015
$28.74M
Jan 20, 2017
Q3
2015
Sep 30, 2014
$22.69M
Jan 20, 2017
Q2
2015
Jun 30, 2014
$29.68M
Aug 7, 2015
Q1
2015
Mar 31, 2014
$9.08M
May 6, 2015
Q3
2014
Sep 30, 2013
$1.26M
Nov 12, 2014
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$192.10M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$165.45M
Aug 5, 2025
Q1
2025
Mar 31, 2025
$149.82M
May 6, 2025
Q3
2025
Sep 30, 2024
$175.69M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$168.33M
Aug 5, 2025
Q1
2025
Mar 31, 2024
$143.64M
May 6, 2025
Q3
2024
Sep 30, 2023
$153.88M
Nov 4, 2024
Q2
2024
Jun 30, 2023
$135.56M
Aug 6, 2024
Q1
2024
Mar 31, 2023
$153.76M
May 8, 2024
Q3
2023
Sep 30, 2022
$177.35M
Nov 8, 2023
Q2
2023
Jun 30, 2022
$170.05M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$152.51M
May 9, 2023
Q3
2022
Sep 30, 2021
$148.46M
Nov 9, 2022
Q2
2022
Jun 30, 2021
$141.33M
Aug 8, 2022
Q1
2022
Mar 31, 2021
$130.93M
May 12, 2022
Q3
2021
Sep 30, 2020
$155.14M
Nov 5, 2021
Q2
2021
Jun 30, 2020
$126.73M
Aug 6, 2021
Q1
2021
Mar 31, 2020
$94.98M
May 7, 2021
Q3
2020
Sep 30, 2019
$102.14M
Nov 6, 2020
Q2
2020
Jun 30, 2019
$104.70M
Aug 17, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2017
Sep 30, 2017
$78.07M
Nov 9, 2017
Q2
2017
Jun 30, 2017
$73.33M
Aug 3, 2017
Q1
2017
Mar 31, 2017
$56.37M
May 9, 2017
Q3
2017
Sep 30, 2016
$55.62M
Nov 9, 2017
Q2
2017
Jun 30, 2016
$50.34M
Aug 3, 2017
Q1
2017
Mar 31, 2016
$43.03M
May 9, 2017
Q3
2016
Sep 30, 2015
$38.55M
Jan 20, 2017
Q2
2016
Jun 30, 2015
$34.27M
Jan 23, 2017
Q1
2016
Mar 31, 2015
$28.10M
Jan 20, 2017
Q3
2015
Sep 30, 2014
$22.45M
Jan 20, 2017
Q2
2015
Jun 30, 2014
$27.61M
Aug 7, 2015
Q1
2015
Mar 31, 2014
$9.00M
May 6, 2015
Q3
2014
Sep 30, 2013
$1.13M
Nov 12, 2014
Q2
2014
Jun 30, 2013
$154.0K
Aug 12, 2014
Q1
2013
Mar 31, 2013
$147.0K
May 15, 2013
Q3
2012
Sep 30, 2012
$91.0K
Nov 2, 2012
Q2
2012
Jun 30, 2012
$91.0K
Aug 13, 2012
Q1
2013
Mar 31, 2012
$208.0K
May 15, 2013
Q3
2012
Sep 30, 2011
$11.0K
Nov 2, 2012
Q2
2012
Jun 30, 2011
$750.0K
Aug 13, 2012
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($45.12M)
Nov 6, 2025
Q3
2025
Jun 30, 2025
$22.50M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$22.50M
Aug 5, 2025
Q1
2025
Mar 31, 2025
($11.83M)
May 6, 2025
Q2
2025
Mar 31, 2025
($11.83M)
Aug 5, 2025
Q3
2025
Mar 31, 2025
($11.83M)
Nov 6, 2025
Q3
2025
Sep 30, 2024
$38.50M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$19.92M
Aug 5, 2025
Q3
2025
Jun 30, 2024
$19.92M
Nov 6, 2025
Q2
2025
Mar 31, 2024
$124.0K
Aug 5, 2025
Q3
2025
Mar 31, 2024
$124.0K
Nov 6, 2025
Q1
2025
Mar 31, 2024
$124.0K
May 6, 2025
Q3
2024
Sep 30, 2023
($15.98M)
Nov 4, 2024
Q2
2024
Jun 30, 2023
($831.0K)
Aug 6, 2024
Q3
2024
Jun 30, 2023
($831.0K)
Nov 4, 2024
Q3
2024
Mar 31, 2023
$16.95M
Nov 4, 2024
Q1
2024
Mar 31, 2023
$16.95M
May 8, 2024
Q2
2024
Mar 31, 2023
$16.95M
Aug 6, 2024
Q3
2023
Sep 30, 2022
$1.75M
Nov 8, 2023
Q3
2023
Jun 30, 2022
$7.87M
Nov 8, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($60.23M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
$12.14M
Aug 5, 2025
Q1
2025
Mar 31, 2025
($10.26M)
May 6, 2025
Q3
2025
Sep 30, 2024
$40.85M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$22.57M
Aug 5, 2025
Q1
2025
Mar 31, 2024
($3.15M)
May 6, 2025
Q3
2024
Sep 30, 2023
$8.14M
Nov 4, 2024
Q2
2024
Jun 30, 2023
($17.59M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
$5.18M
May 8, 2024
Q3
2023
Sep 30, 2022
($1.52M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
$11.35M
Aug 8, 2023
Q1
2023
Mar 31, 2022
$1.97M
May 9, 2023
Q3
2022
Sep 30, 2021
$32.60M
Nov 9, 2022
Q2
2022
Jun 30, 2021
$34.11M
Aug 8, 2022
Q1
2022
Mar 31, 2021
$13.21M
May 12, 2022
Q3
2021
Sep 30, 2020
$56.14M
Nov 5, 2021
Q2
2021
Jun 30, 2020
$45.55M
Aug 6, 2021
Q1
2021
Mar 31, 2020
$29.01M
May 7, 2021
Q3
2020
Sep 30, 2019
$39.73M
Nov 6, 2020
Q2
2020
Jun 30, 2019
$42.60M
Aug 17, 2020